Untitled 3

Source R&D is the authoritative source of technology and services information supporting pharmaceutical and biotechnology companies in their drug discovery and development research projects.

Source R&D features extensive listings of service providers classified under company or organisation type, including contract chemical manufacturers; contract biologics manufacturers; biological research companies and organisations; and companies and organisations providing advisory, consultancy, legal, regulatory and other services.

The extensive coverage of Source R&D and the support of life sciences organisations One Nucleus and Bionow make it an invaluable reference tool that streamlines the vendor selection process to bring pharmaceutical/biotechnology companies and suppliers together.

TxCell appoints Lonza as CAR-Treg cellular product manufacturer

TxCell SA, a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, and Lonza Pharma & Biotech have entered into a Master Service Agreement for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200)…
  • Published in Source R&D
  • Read: 334 times

IONTAS and aTen Therapeutics in oncology collaboration

IONTAS Limited, a specialist in the discovery and optimisation of fully human antibodies,and aTen Therapeutics Limited, a biopharmaceutical company developing next-generation antibodies for the treatment of cancer, have entered into a strategic collaboration in which IONTAS will use its proprietary…

Isogenica licenses CIS Display Technology to Fusion Pharmaceuticals

Isogenica and Fusion Pharmaceuticals have formed a licensing agreement that will combine the two companies’ expertises in recombinant protein technologies and radiopharmaceutical development. Isogenica specialises in the design and construction of highly diverse synthetic antibody libraries and the use of…

Zelluna Immunotherapy appoints Arjan Roozen as CTO

Zelluna Immunotherapy, a specialist in T-cell receptor (TCR) immunotherapies for cancer has appointed Arjan Roozen as chief technology officer (CTO). According to Miguel Forte, Zelluna’s CEO, the company appointed Roozen specifically for his wide-ranging knowledge in key areas of cell…
  • Published in Source R&D
  • Read: 397 times

AstraZeneca uses breath biopsy to study asthma, COPD disease drivers

Owlstone Medical has signed a service agreement to supply breath biopsy services to AstraZeneca for the identification of novel biomarkers to help differentiate between disease phenotypes relevant for asthma and COPD. The services will include the development of classification algorithms…
  • Published in Source R&D
  • Read: 386 times

Certara launches QSP Immuno-oncology Simulator Consortium

Certara has launched its Quantitative Systems Pharmacology (QSP) Immuno-oncology Simulator Consortium to support the application of computational modelling and experimental methods in examining the mechanistic relationships between a drug, the biological system, and the disease process. QSP integrates quantitative drug…
  • Published in Source R&D
  • Read: 509 times

IONTAS and IGEM Therapeutics to collaborate on anti-cancer antibodies

IONTAS Limited, a specialist in the discovery and optimisation of fully human antibodies, is to collaborate with immuno-oncology company IGEM Therapeutics on developing novel immunoglobulin E (IgE) antibodies for cancer treatment. The project will add to IGEM’s pipeline of drugs…
  • Published in Source R&D
  • Read: 439 times

JXTG Energy sells Irvine Scientific to FujiFilm

JXTG Nippon Oil & Energy Corporation is to sell Irvine Scientific Sales Company, Inc and IS Japan Co, Ltd to FUJIFILM Corporation. JXTG Energy acquired Irvine Scientific in 1987 and launched IS Japan in 1989: both companies have continuously expanded to…
  • Published in Source R&D
  • Read: 458 times

Gyros Protein Technologies introduces Gyrolab xPand to improve immunoassay workflow in biotherapeutic discovery, development and production

Gyros Protein Technologies has introduced its Gyrolab® xPand immunoassay platform to provide higher throughput, greater flexibility and faster analysis of large sample numbers in biotherapeutic development. The new platform features more advanced instrumentation and software that are designed to ensure 21 CFR…
  • Published in Source R&D
  • Read: 410 times
Subscribe to this RSS feed